Welireg (Belzutifan) Patent Expiration, LOE Window & CMS Spending

Welireg (Belzutifan) by Merck & Co.: FDA Orange Book core substance LOE 2034-09-05 (last listed 2042-06-30), 0 AB generics, $233.4M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMerck & Co.
FDA Application & PathwayN215383 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2034-09-05
Last Listed Patent or Exclusivity Date2042-06-30
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$233.4M
2024 Medicare Part D Spend$205.5M
2024 Medicaid Spend$28.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.